The first domestic self-research "Liejing" is here!

The first domestically developed SGLT-2 inhibitor

The launch meeting of the first domestic innovative SGLT-2 inhibitor Proline Henggliflozin Tabletsindependently developed by Hengrui Medicine and the Hengrui Diabetes Pipeline Launch Conference were held a few days a.

Hengrui’s announcement stated that Henggliflozin is a new and highly selective oral inhibitor of SGLT- The data from two phase III clinical studies show that Henggliflozin is effective in monotherapy and in combination with metform.

Data from a Phase 3 clinical study of henpagliflozin combined with metformin in the treatment of type 2 diabetes (T2DM) have been published in Diabetes Obes Met.

Sun Piaoyang, chairman of Hengrui, said that Hengrui is the first category 1 innovative drug launched by Hengrui in the field of diabetes; in the future, Hengrui will fully deploy the diabetes product pipeli.

Global market performance of SGLT2 inhibitors

SGLT2 inhibitors, namely sodium-glucose co-transporters 2 (sodium-dependent glucose transporters 2, SGLT-2) inhibitors, have a unique insulin-independent hypoglycemic mechanism, which can inhibit the reabsorption of glucose by the kidneys and make excessive gluco.

Globally listed SGLT2 inhibitors include AstraZeneca's Dapagliflozin, Johnson & Johnson's Canagliflozin, Boehringer Ingelheim's Empagliflozin, Merck's Aigliflozin, and Sanofi's Soxagliflozin , Ipagliflozin from Astellas Pharmaceuticals, Topagliflozin from Zhongwai Pharmaceutical and Lupagliflozin from Taisho Pharma

According to the EvaluatePharma database, the global sales of SGLT2 inhibitor-related products in 2020 are about US$681 billion , while the sales of the two brothers, empagliflozin and dapagliflozin alone, will exceed US$8 billion in 2021, with rapid grow.

In terms of Boehringer Ingelheim, Engley's net sales in 2021 are approximately 9 billion euros (06 billion.

AstraZeneca’s dapagliflozin net global sales in 2020 will reach $ 959 billion , and sales in 2021 will be $3 billion , a year-on-year increase of 49%

Johnson & Johnson's canagliflozin has been left far behind by Enda, with global sales of $563 million in 2021, down 23%

The domestic market broke out and began to "involute" at the same time

According to data from Min.

Although "Liejing" hypoglycemic drugs have been "popular" in the global hypoglycemic drug market for a period of time, due to the fact that they have not entered the domestic market for a long time, and the domestic hypoglycemic drug market has long been dominated by traditional hypoglycemic drugs such as insulin , "Liejing" and other new hypoglycemic drugs have not come to the forefro.

However, according to the data from Min.

(Source: Mine Database)

The market share of Dapagliflozin, the first SGLT2 inhibitor to enter the country, increased from 79% to 51% , while the terminal sales of sample hospitals in 2021 were 452 million yuan and 190 million yuan in 2020, a year-on- year increase of 1392.

In addition, both empagliflozin and canagliflozin were included in the fourth batch of centralized procurement, and their performance in 2021 is also go.

With reference to the global performance of the original new hypoglycemic drugs, it is certain that these new generation hypoglycemic drugs (SGLT2 inhibitors, GLP-1 receptor agonists, e.

) will gradually replace traditional oral hypoglycemic drugs in the future in Chi.

Domestic companies have already sensed opportunities, and more and more manufacturers have deployed SGLT2 inhibitors in recent years, and the situation has begun to "involut.

2, 5 and 3 manufacturers of dapagliflozin, empagliflozin and canagliflozin have been approved to produce generic drugs, respectively, and 7, 6 and 4 are in the application of generic drug listing

Not only will the imitation compete with the original research, but the competition between varieties will become more and more fier.

In addition to Hengglijing, which has joined the battle, there are also Sihuan Pharmaceutical's innovative drug Jiagliflozin in the stage of listing application, and some other drugs in the clinical sta.

It is unavoidable to "roll up" the domestically produced n.

It is worth mentioning that, in addition to the good effect of reducing blood sugar and weight loss, “Liejing” products have been proven to be effective for certain cardiovascular and renal diseases abro.

For such a “treasure” hypoglycemic drug, it seems natural that the competition is fier.

_